Current:Home > InvestCOVID test kits, treatments and vaccines won't be free to many consumers much longer-LoTradeCoin
COVID test kits, treatments and vaccines won't be free to many consumers much longer
View Date:2024-12-23 23:56:26
Time is running out for free-to-consumer COVID-19 vaccines, at-home test kits and even some treatments.
The White House announced this month that the national public health emergency, first declared in early 2020 in response to the pandemic, is set to expire May 11. When it ends, so will many of the policies designed to combat the virus's spread.
COVID vaccine makers are poised to raise prices
Take vaccines. Until now, the federal government has been purchasing COVID-19 shots. It recently bought 105 million doses of the Pfizer-BioNTech bivalent booster for about $30.48 a dose, and 66 million doses of Moderna's version for $26.36 a dose. (These are among the companies that developed the first COVID vaccines sold in the United States.)
People will be able to get these vaccines at low or no cost as long as the government-purchased supplies last. But even before the end date for the public emergency was set, Congress opted not to provide more money to increase the government's dwindling stockpile. As a result, Pfizer and Moderna were already planning their moves into the commercial market. Both have indicated that as soon as that happens, they will raise the price they charge, somewhere in the range of $110 to $130 per dose, though insurers and government health programs could negotiate lower rates.
"We see a double-digit billion[-dollar] market opportunity," investors were told at a JPMorgan conference in San Francisco recently by Ryan Richardson, chief strategy officer for BioNTech. The company expects a gross price — the full price before any discounts — of $110 a dose, which, Richardson said, "is more than justified from a health economics perspective."
That could translate to tens of billions of dollars in revenue for the manufacturers, even if uptake of the vaccines is slow. And consumers would foot the bill, either directly (in copays) or indirectly (through higher premiums and taxpayer-funded subsidies).
If half of adults — about the same percentage as those who opt for an annual flu shot — get a COVID shot at the new, higher prices, a recent KFF report estimated, insurers, employers and other payors would shell out $12.4 billion to $14.8 billion. That's up to nearly twice as much as what it would have cost for every adult in the U.S. to get a bivalent booster at the average price paid by the federal government.
As for COVID treatments, an August blog post by the Department of Health and Human Services' Administration for Strategic Preparedness and Response noted that government-purchased supplies of the drug Paxlovid are expected to last at least through midyear before the private sector takes over. The government's bulk purchase price from manufacturer Pfizer was $530 for a course of treatment, and it isn't yet known what the companies will charge once government supplies run out.
The type of health insurance you have will determine how much more you'll pay
One thing is certain: How much, if any, of the boosted costs are passed on to consumers will depend on their health coverage.
Medicare beneficiaries, those enrolled in Medicaid — the state-federal health insurance program for people with low incomes — and people who have health plans via the Affordable Care Act exchanges will continue to get COVID-19 vaccines without charge, even when the public health emergency ends and the government-purchased vaccines run out. Many people with job-based insurance will also likely not face copayments for vaccines, unless they go out-of-network for their vaccinations.
People with limited-benefit or short-term insurance policies might have to pay for all or part of their vaccinations. And people who don't have insurance will need to either pay full cost out-of-pocket or seek no- or low-cost vaccinations from community clinics or other providers. If they cannot find a free or low-cost option, some uninsured patients may feel forced to skip vaccinations or testing.
Coming up with what could be $100 or more for vaccination will be especially hard "if you are uninsured or underinsured; that's where these price hikes could drive additional disparities," said Sean Robbins, executive vice president of external affairs for the Blue Cross Blue Shield Association. Those increases, he said, will also affect people with insurance, as the costs "flow through to premiums."
COVID-19 treatments will cost more, too.
Meanwhile, public policy experts say many private insurers will continue to cover Paxlovid, although patients may face a copayment, at least until they meet their deductible, just as they do for other medications. Medicaid will continue to cover it without cost to patients until at least 2024.
Medicare beneficiaries will face cost-sharing for most COVID-19 treatments once the emergency officially ends and the government supply runs out. Meanwhile, the treatment will also need to go through the regular FDA approval process, which takes longer than the emergency use authorization under which it has been marketed
Another complication: The rolls of the uninsured are likely to climb in the next year, with states poised to reinstate the process of regularly determining Medicaid eligibility; that sort of review was halted during the pandemic. In April, states will begin reassessing whether Medicaid enrollees meet income and other qualifying factors.
An estimated 5 million to 14 million people nationwide might lose coverage.
"This is our No. 1 concern" right now, said John Baackes, CEO of L.A. Care, the nation's largest publicly operated health plan with 2.7 million members.
"They may not realize they've lost coverage until they go to fill a prescription" or seek other medical care, including vaccinations, he said.
At-home COVID tests won't be free for many people
Rules remain in place for insurers, including Medicare and Affordable Care Act plans, to cover the cost of up to eight in-home test kits a month for each person on the plan, until the public health emergency ends.
For consumers — including those without insurance — a government website is still offering up to four test kits per household, until they run out. The Biden administration shifted funding to purchase additional kits and made them available in late December.
Starting in May, though, beneficiaries in original Medicare and many people with private, job-based insurance will have to start paying out-of-pocket for the rapid antigen test kits. Some Medicare Advantage plans, which are an alternative to original Medicare, might opt to continue covering them without a copayment. Policies will vary, so check with your insurer. And Medicaid enrollees can continue to get the test kits without cost into mid-2024.
Overall, the future of COVID tests, vaccines and treatments will reflect the complicated mix of coverage consumers already navigate for most other types of care.
"From a consumer perspective, vaccines will still be free, but for treatments and test kits, a lot of people will face cost-sharing," said Jen Kates, a senior vice president at KFF. "We're taking what was universal access and now saying we're going back to how it is in the regular U.S. health system."
KHN correspondent Darius Tahir contributed to this report. KHN (Kaiser Health News) is a national, editorially independent program of KFF (Kaiser Family Foundation).
veryGood! (47)
Related
- Satire publication The Onion acquires Alex Jones' Infowars at auction
- Iris Apfel, fashion icon who garnered social media fame in her later years, dies at 102
- Man charged with attacking police in Times Square, vilified in Trump ad, was misidentified, DA says
- Caitlin Clark breaks Pete Maravich's all-time scoring record as Iowa beats Ohio State
- RHOBH's Erika Jayne Reveals Which Team She's on Amid Kyle Richards, Dorit Kemsley Feud
- Patient and 3 staffers charged in another patient’s beating death at mental health facility
- In Hawaii, coral is the foundation of life. What happened to it after the Lahaina wildfire?
- NASCAR Las Vegas race March 2024: Start time, TV, streaming, lineup for Pennzoil 400
- Opinion: Chris Wallace leaves CNN to go 'where the action' is. Why it matters
- A 4-year-old Gaza boy lost his arm – and his family. Half a world away, he’s getting a second chance
Ranking
- Democrat Cleo Fields wins re-drawn Louisiana congressional district, flipping red seat blue
- Nikki Haley wins the District of Columbia’s Republican primary and gets her first 2024 victory
- Former NFL player Braylon Edwards saves 80-year-old man from gym locker room attack
- MLB's few remaining iron men defy load management mandates: 'Why would I not be playing?'
- Watch out, Temu: Amazon Haul, Amazon's new discount store, is coming for the holidays
- Pennsylvania woman faces life after conviction in New Jersey murders of father, his girlfriend
- Jake Paul vs. Ryan Bourland live updates: How to watch, stream Jake Paul fight card
- Northern California battered by blizzard, Sierra Nevada residents dig out: See photos
Recommendation
-
2 more escaped monkeys recaptured and enjoying peanut butter and jelly sandwiches in South Carolina
-
How are big names like Soto, Ohtani, Burnes doing with new teams in MLB spring training?
-
Blizzard hits California and Nevada, shutting interstate and leaving thousands without power
-
Angel Reese and her mother had a special escort for LSU's senior day: Shaq
-
Video ‘bares’ all: Insurers say bear that damaged luxury cars was actually a person in a costume
-
Trump escalates his immigration rhetoric with baseless claim about Biden trying to overthrow the US
-
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
-
Georgia teen critically injured after police trade gunfire with a group near Six Flags